List of Excipients in Branded Drug EXONDYS 51

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sarepta Therapeutics Inc	EXONDYS 51	eteplirsen	60923-363	HYDROCHLORIC ACID	2029-02-02
Sarepta Therapeutics Inc	EXONDYS 51	eteplirsen	60923-363	POTASSIUM CHLORIDE	2029-02-02
Sarepta Therapeutics Inc	EXONDYS 51	eteplirsen	60923-363	POTASSIUM PHOSPHATE, MONOBASIC	2029-02-02
Sarepta Therapeutics Inc	EXONDYS 51	eteplirsen	60923-363	SODIUM CHLORIDE	2029-02-02
Sarepta Therapeutics Inc	EXONDYS 51	eteplirsen	60923-363	SODIUM HYDROXIDE	2029-02-02

Exondys 51 Excipient Strategy and Commercial Opportunities

Last updated: August 19, 2026

Exondys 51 is an intravenously administered eteplirsen solution for Duchenne muscular dystrophy patients with a confirmed mutation amenable to exon 51 skipping. Its formulation uses a low-complexity excipient system: sodium chloride, water for injection, and pH adjustment with hydrochloric acid and sodium hydroxide. The commercial opportunity is therefore concentrated in sterile manufacturing, fill-finish capacity, packaging, supply reliability, infusion compatibility, and differentiated presentation rather than in complex formulation science.

The product’s formulation has limited apparent excipient-based differentiation. A competing manufacturer would likely need to establish clinical, regulatory, or operational advantages through a new dosage form, reduced infusion burden, improved stability, lower container-closure cost, or more efficient administration.

What is Exondys 51 and how is it formulated?

Exondys 51 contains eteplirsen, a phosphorodiamidate morpholino oligomer designed to induce exon 51 skipping in dystrophin pre-mRNA. It is supplied as a sterile, preservative-free intravenous solution at a concentration of 50 mg/mL.

The approved presentation is administered once weekly at a dose of 30 mg/kg by intravenous infusion over approximately 35 to 60 minutes, according to the U.S. prescribing information.[1]

Formulation attribute	Exondys 51 profile
Active ingredient	Eteplirsen
Drug class	Antisense phosphorodiamidate morpholino oligomer
Route	Intravenous infusion
Approved dose	30 mg/kg once weekly
Concentration	50 mg/mL
Primary container	Single-dose vial
Preservative	None
Key excipients	Sodium chloride, water for injection
pH adjustment	Hydrochloric acid and sodium hydroxide
Indication	Duchenne muscular dystrophy amenable to exon 51 skipping
FDA approval	Accelerated approval, Sept. 19, 2016
Sponsor	Sarepta Therapeutics

The formulation is an aqueous saline product. It does not depend on a lipid nanoparticle, polymeric carrier, surfactant, co-solvent, lyophilized cake, or other advanced delivery platform.

What excipients are used in Exondys 51?

The excipient system is designed primarily to provide isotonicity, pH control, and compatibility with intravenous administration.

Sodium chloride

Sodium chloride provides tonicity and supports the product’s osmolality profile. Its use is commercially attractive because it is inexpensive, widely available, and supported by extensive injectable-product precedent.

Hydrochloric acid and sodium hydroxide

These agents adjust the final pH during manufacture. They are process excipients rather than meaningful formulation differentiators. Their commercial importance is tied to process control, pH specification, and batch consistency.

Water for injection

Water for injection is the vehicle. The product is therefore dependent on pharmaceutical-grade water systems, aseptic processing, and validated sterile filtration or equivalent sterile-manufacturing controls.

Preservative-free design

The single-dose, preservative-free presentation reduces concerns associated with repeated-dose antimicrobial preservatives and is consistent with an intravenous product used in pediatric and adolescent patients. The tradeoff is that each vial must meet single-use sterile-product requirements and cannot rely on multidose preservation.

How strong is the Exondys 51 formulation strategy?

The formulation strategy is operationally robust but technically narrow. Its strengths are simplicity, low excipient burden, established injectable components, and a direct path to commercial-scale manufacturing. Its limitations are the absence of a strong formulation barrier and the continuing dependence on aseptic fill-finish capacity.

Factor	Assessment
Excipient complexity	Low
Raw-material availability	High
Formulation development risk	Low to moderate
Sterile manufacturing risk	Moderate to high
Device dependence	Low
Opportunity for excipient substitution	Limited
Opportunity for improved presentation	Moderate
Potential formulation-patent strength	Likely limited relative to active-ingredient or manufacturing claims
Supply-chain sensitivity	High because of weekly weight-based dosing
Patient and caregiver burden	Material because of weekly infusion

The product’s principal technical barrier is not the excipient system. It is the manufacture, characterization, release testing, and clinical performance of the morpholino oligomer, combined with sterile intravenous production.

What commercial opportunities exist in Exondys 51 excipients?

The largest opportunities involve enabling materials and manufacturing services rather than premium excipient sales.

Sterile fill-finish services

Exondys 51 requires sterile vial production with reliable control of bioburden, endotoxin, particulate matter, container closure integrity, and fill accuracy. Contract manufacturers with capacity for low-to-moderate-volume sterile biologic or oligonucleotide products can target:

• Aseptic vial filling
• Sterile filtration
• Visual inspection
• Lyophilization capacity if a future reformulation uses a dry presentation
• Automated labeling and serialization
• Cold-chain packaging and distribution

A manufacturer would need validated compatibility with the formulation, vial, stopper, and production equipment. Extractables and leachables control is important because the product is administered intravenously and may remain in contact with elastomeric components during storage.

Pharmaceutical-grade sodium chloride

Sodium chloride is a commodity excipient, so price-based differentiation is weak. Suppliers can create value through:

• Injectable-grade quality systems
• Lot-to-lot consistency
• Reduced microbial and endotoxin risk
• Regional supply redundancy
• Documentation supporting regulatory submissions
• Qualified secondary sources

The opportunity is strongest as part of an integrated sterile-product supply package rather than as a standalone ingredient.

Container-closure systems

The vial and stopper system offers a more defensible commercial opportunity than sodium chloride. Potential value propositions include:

• Low-extractable elastomeric stoppers
• Improved container-closure integrity
• Reduced product adsorption
• Better resistance to needle coring
• Smaller vial formats that reduce waste
• Packaging that supports temperature excursions
• Ready-to-use presentations for hospital pharmacies

For a weight-based pediatric therapy, vial size and fill volume affect pharmacy waste, preparation time, and acquisition economics. A presentation that reduces partial-vial waste could create value without changing the active ingredient.

Infusion compatibility and administration systems

Exondys 51 is diluted before intravenous infusion, creating opportunities for validated administration materials. Suppliers could develop or qualify:

• Compatible infusion bags
• Low-sorption tubing
• Closed-system transfer devices
• Pharmacy compounding adapters
• Ready-to-administer bags
• Standardized dilution and transfer kits

Any such system would need compatibility data showing that eteplirsen concentration, purity, particulate levels, and recovery remain within specification over the labeled preparation and administration period.

Ready-to-use presentations

A ready-to-use or pharmacy-prepared presentation could reduce manipulation and preparation time. The commercial case would depend on:

• Stability after dilution
• Container compatibility
• Shipping volume
• Dose variability based on patient weight
• Hospital pharmacy workflow
• Reimbursement treatment
• Waste reduction

Because the dose is weight-based, a single fixed-dose ready-to-use bag may not fit all patients. A portfolio of dose bands or pharmacy-ready concentrations could be more practical than one universal presentation.

What formulation patents protect Exondys 51?

The strongest proprietary protection for Exondys 51 is more likely to involve eteplirsen composition, sequence, therapeutic use, exon-skipping methods, and manufacturing than the basic saline formulation.

The public product profile does not indicate a technically complex excipient platform comparable to a nanoparticle, depot, sustained-release system, or proprietary protein-stabilization system. A formulation challenger would therefore examine:

1. Claims covering aqueous eteplirsen compositions.
2. Claims covering concentration ranges.
3. Claims covering pH or osmolality ranges.
4. Claims covering vial or container-closure configurations.
5. Claims covering dilution and administration procedures.
6. Claims covering manufacturing or purification of the morpholino oligomer.
7. Claims covering exon 51 skipping and treatment of Duchenne muscular dystrophy.

Patent strength should be assessed claim by claim. A narrow claim to a specific sodium chloride concentration or pH range may be vulnerable if the range is predictable from prior art. Manufacturing claims may be more difficult to design around if they cover critical purification, impurity-control, or chain-length attributes of eteplirsen.

Publicly available product information alone does not establish the current complete patent-family status, Orange Book listing status, terminal disclaimers, patent-term adjustments, or litigation posture. Those issues require review of the FDA Orange Book, USPTO records, and active court dockets.[1-3]

When does Exondys 51 lose exclusivity?

Exondys 51 received accelerated approval in 2016. Its regulatory exclusivity and patent protection should be analyzed separately.

FDA regulatory exclusivity

The FDA granted Exondys 51 seven years of orphan-drug exclusivity under the Orphan Drug Act. Orphan exclusivity generally blocks approval of the same drug for the same disease or condition during the exclusivity period, subject to statutory exceptions.[4]

The product also received approval under the accelerated-approval pathway. Accelerated approval does not itself create a fixed long-term market monopoly equivalent to patent protection. It creates regulatory obligations concerning confirmatory evidence and can create withdrawal risk if required verification is not completed or does not confirm benefit.[1,5]

Patent exclusivity

Patent expiry cannot be stated accurately from the product label alone. Relevant dates may include:

• Patent expiration
• Patent-term adjustment
• Patent-term extension
• Terminal disclaimer effects
• Pediatric exclusivity
• Patent reissue or continuation status
• Orange Book listing and delisting history

For commercial planning, the earliest credible generic or alternative-product entry date should be modeled as a range based on the enforceability of active-ingredient, method-of-use, formulation, and manufacturing patents.

Is there biosimilar risk for Exondys 51?

Traditional biosimilar risk is limited because Exondys 51 is a synthetic antisense oligomer rather than a protein biologic. The product is not expected to face biosimilar competition under the same framework used for monoclonal antibodies, recombinant proteins, or other large biologics.

The more relevant risks are:

• A 505(b)(2) product with a modified formulation or presentation
• A competing eteplirsen product using a different manufacturing process
• An alternative exon-skipping therapy
• Other Duchenne treatments that reduce infusion demand
• Patient-specific competition from exon 45, exon 53, or other mutation-targeted therapies

The regulatory pathway for a follow-on eteplirsen product would depend on the proposed product’s sameness, clinical reliance, formulation differences, manufacturing process, and applicable FDA requirements. A simple excipient substitution would not automatically remove the need to demonstrate product quality and therapeutic equivalence.

What FDA regulatory issues affect excipient opportunities?

The key FDA issues are product quality and administration performance.

Critical quality attributes

A reformulated or follow-on product would need control over:

• Eteplirsen identity and assay
• Related substances and impurities
• Oligomer chain integrity
• pH
• Osmolality
• Particulate matter
• Sterility
• Endotoxin
• Container-closure integrity
• Stability under labeled storage conditions

For oligonucleotide products, impurity profiles and analytical comparability can be more important than the identity of common excipients. A change from one source of sodium chloride to another is unlikely to be commercially meaningful unless it affects impurity control, process yield, or regulatory supply qualification.

Dilution stability

Because the product is prepared for infusion, dilution stability is a commercial differentiator. Useful data would cover:

• Dilution in commonly used infusion fluids
• Hold time at room temperature
• Refrigerated storage
• Light exposure
• Contact with infusion bags and tubing
• Recovery after transfer
• Particulate formation
• Chemical degradation

A product or administration kit supported by broader compatibility data could reduce hospital pharmacy friction.

Which companies are positioned to challenge or supply Exondys 51?

Sarepta Therapeutics is the originator and commercial sponsor. Competitive pressure is more likely to come from Duchenne therapeutics developers than from conventional excipient suppliers.

The competitive landscape includes:

Competitive category	Commercial relevance
Follow-on eteplirsen	Could compete on price, supply, or administration
Other exon-skipping therapies	Mutation-specific substitutes
Gene therapy	Potentially reduces demand for chronic weekly infusion
Corticosteroid therapy	Background standard of care, not a direct replacement
Small-molecule Duchenne therapies	May compete for treatment budgets and clinical attention
Contract manufacturers	Potential partners for supply and fill-finish
Vial and infusion-system suppliers	Can reduce preparation cost and waste

The most significant strategic threat is modality competition. A successful one-time or less-frequent therapy could reduce the value of a weekly intravenous product even if Exondys 51 remains clinically useful for eligible patients.

What generic launch risks exist for Exondys 51?

A generic launch would face several barriers:

1. The active ingredient is a complex synthetic oligomer rather than a conventional small molecule.
2. The target population is genetically defined.
3. Clinical performance depends on exon-skipping activity and dystrophin-related outcomes.
4. Manufacturing and impurity control may be difficult to reproduce.
5. Patent claims may cover therapeutic use or manufacturing.
6. Market size is limited to patients amenable to exon 51 skipping.
7. Weekly weight-based dosing increases inventory and pharmacy complexity.

A lower-cost follow-on product could still attract payers if it demonstrates comparable quality and clinical performance. The most credible near-term commercial opportunity is a differentiated administration or supply model, not a simple excipient copy.

How does Exondys 51 compare with other Sarepta exon-skipping products?

Exondys 51, Vyondys 53, and Amondys 45 share a broad product concept but target different dystrophin exons and patient mutations. Their formulation and commercial strategies are likely to show operational overlap, including sterile injectable manufacturing, vial supply, infusion preparation, and specialized distribution.

Product	Active ingredient	Target exon	Administration model
Exondys 51	Eteplirsen	51	Weekly IV infusion
Vyondys 53	Golodirsen	53	Weekly IV infusion
Amondys 45	Casimersen	45	Weekly IV infusion

The shared platform may allow Sarepta or its suppliers to consolidate procurement, analytical methods, fill-finish operations, and hospital pharmacy support. A supplier that qualifies materials across the franchise could have greater commercial value than one supporting Exondys 51 alone.

What licensing opportunities exist around Exondys 51 excipients?

Potential licensing structures include:

• Regional sterile fill-finish agreements
• Dual-source excipient qualification
• Low-extractable vial and stopper platforms
• Ready-to-administer infusion systems
• Stability-enhancing packaging
• Hospital pharmacy preparation systems
• Manufacturing technology for eteplirsen impurity reduction
• Contract analytical testing for oligomer identity and purity

Licensing value will depend on whether the technology reduces cost, improves supply continuity, shortens preparation time, or creates a regulatory advantage. A common excipient without protected manufacturing or quality attributes is unlikely to command significant licensing economics.

Key Takeaways

• Exondys 51 uses a simple aqueous injectable formulation centered on sodium chloride, water for injection, and pH adjustment.
• The principal commercial barriers are sterile manufacturing, oligomer quality control, packaging, and supply reliability.
• Excipient substitution alone offers limited differentiation.
• Vial design, container closure, infusion compatibility, dilution stability, and ready-to-administer formats offer stronger commercial opportunities.
• Traditional biosimilar risk is limited because eteplirsen is a synthetic antisense oligomer, not a conventional protein biologic.
• Follow-on competition could arise through 505(b)(2)-type strategies, alternative manufacturing processes, or improved administration systems.
• Patent analysis must separate active-ingredient, method-of-use, formulation, manufacturing, and container-related claims.
• The largest strategic threat is competition from other Duchenne modalities, particularly therapies that reduce the need for chronic weekly infusion.

FAQs

Can Exondys 51 be reformulated as a subcutaneous injection?

A subcutaneous reformulation would require new development work addressing local tolerability, injection volume, absorption, exposure, and clinical comparability. The current product is approved for intravenous infusion.

Does Exondys 51 need a preservative?

The approved product is preservative-free and supplied as a single-dose vial. A multidose presentation would require a separate preservative, container, sterility, and stability assessment.

Can sodium chloride be replaced in an Exondys 51 follow-on product?

Potentially, but the substitute would need to preserve osmolality, stability, tolerability, and compatibility with the active ingredient and container-closure system. The regulatory impact would depend on the extent of the formulation change.

Is a prefilled syringe commercially practical for eteplirsen?

A prefilled syringe could reduce pharmacy handling but may be impractical for a high-dose, weight-based therapy requiring variable volumes. Device compatibility, injection volume, viscosity, dose accuracy, and stability would determine feasibility.

What is the highest-value excipient opportunity for Exondys 51?

The highest-value opportunity is likely an integrated package combining low-extractable container-closure components, validated infusion compatibility, dilution stability, and sterile fill-finish capacity. Commodity sodium chloride alone is unlikely to provide comparable differentiation.

References

1. U.S. Food and Drug Administration. (2024). Exondys 51 (eteplirsen) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. United States Patent and Trademark Office. (2024). Patent Center and patent term adjustment records.
4. U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity.
5. U.S. Food and Drug Administration. (2024). Accelerated approval program.
6. Sarepta Therapeutics, Inc. (2024). Annual report on Form 10-K.